Current and Potential Treatment of Tuberculosis

Drugs

Volumn 48, Issue 5, 1994, Pages 689-708

  Houston, Stan ^a   Fanning, Anne ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; BETA LACTAM ANTIBIOTIC; CLOFAZIMINE; CORTICOSTEROID; CYCLOSERINE; CYCLOSPORIN; ETHAMBUTOL; ETHIONAMIDE; GLUCOCORTICOID; ISONIAZID; KETOCONAZOLE; LEVAMISOLE; MACROLIDE; PYRAZINAMIDE; QUINOLONE; RIFAMPICIN; RIFAMYCIN; STREPTOMYCIN; SULFONYLUREA; THEOPHYLLINE; THIOACETAZONE; UNINDEXED DRUG;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TUBERCULOSIS; NAUSEA; NONHUMAN; OTOTOXICITY; PATIENT COMPLIANCE; PIGMENT DISORDER; PREGNANCY; PSYCHOSIS; RASH; REVIEW; TUBERCULOSIS; TUBERCULOUS SPONDYLITIS; VISUAL DISORDER; VOMITING;

ANIMAL; ANTITUBERCULAR AGENTS; HUMAN; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0028027382     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199448050-00004     Document Type: Article

References (164)

1. Estimates of future global tuberculosis morbidity and mortality
2. Medicine: the public good and one’s own
3. Tuberculosis in developing counties: burden, intervention and costs
4. Tuberculosis in Eskimos
5. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries
6. The association of the risk of tuberculosis infection with age
7. An address on bacteriological research delivered before the International Medical Congress, Berlin 1890
8. The effect of streptomycin upon pulmonary tuberculosis
9. Streptomycin treatment of pulmonary tuberculosis
10. Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation
11. Comment: intravenous streptomycin [letter]
12. Ethambutol: a review with special reference to ocular toxicity
13. Update on rifampin drug interactions
14. Pharmacokinetic drug interactions wth rifampi-cin
15. Isoniazid with thiacetazone in the treatment of pulmonary tuberculosis in East Africa — second investigation
16. Thiacetazone — a review
17. Isoniazid with thiacetazone (thiacetazone) in the treatment of pulmonary tuberculosis in East Africa — fifth investigation
18. A conrolled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore: second report
19. An international co-operative investigation into thiacetazone (thiacetazone) side-effects
20. A second international cooperative investigation into thiacetazone side effects
21. Stevens-Johnson syndrome, erythema multiform pluriorificialis, in association with the administration of thiosemicarbasone
22. Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania
23. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis
24. The influence of HIV status on single and multiple drug reactions to antituber-culous therapy in Africa
25. Treatment of tuberculosis and tuberculosis infection in adults and children
26. Antituberculosis drugs: pharmacokinetics
27. Mycobacteria and the new quinolones
28. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis
29. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis
30. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice
31. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin and ethambutol [letter]
32. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS
33. Rifabutin prophylaxis against Mycobacterium avium complex infection [letter]
34. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis
35. Treatment of disseminated disease dddue to Mycobacterium avium complex in patients with AIDS
36. The synergistic effects of gamma-inter-feron and clofazimine on phagocyte function: restoration of inhibition due to a 25 Kilodalton fraction from Mycobacterium tuberculosis
37. Levamisole as an adjunct in the treatment of pulmonary tuberculosis
38. Corticosteroids and tuberculosis: risks and use as adjunct therapy
39. Controlled trial of prednisone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei
40. Controlled clinical trial of complete open surgical drainage and prednisone in the treatment of tuberculous pericardial effusion in Transkei
41. Corticosteroids in the treatment of tuberculous pleurisy
42. Cold and consumption: Canada and the climatic treatment of tuberculosis
43. The modern management and therapy of pulmonary tuberculosis
44. The surgery for pulmonary tuberculosis
45. Ten-year experience with artificial pneumoperitoneum for end-stage, drug-resistant pulmonary tuberculosis
46. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis
47. New concepts for the control of tuberculosis in the twenty-first century
48. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis
49. Short-course chemotherapy in pulmonary tuberculosis
50. A controlled trial of six months chemotherapy in pulmonary tuberculosis
51. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin
52. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis
53. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis
54. Controlled clinical trial of four short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report
55. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis
56. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis
57. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin
58. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide
59. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis
60. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India
61. Shortest possible acceptable effective chemotherapy in ambulatory patients with pulmonary tuberculosis
62. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis
63. Evaluation of the results of short-course chemotherapy in Mozambique, 1985-1987
64. Ten years of the National Tuberculosis/Leprosy Programme in Tanzania
65. The Malawi National Tuberculosis Programme
66. Evolution of case-finding and treatment of tuberculosis over the last 3 years following the introduction of short-course chemotherapy of 8 months duration in Benin
67. The tuberculosis manyatta project for Kenyan nomads
68. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis
69. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland
70. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis
71. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore, the results up to 30 months
72. A study of two twice weekly and a once weekly continuation regimen of tuberculosis chemotherapy including a comparison of two durations of treatment: results at 36 months
73. Study of a fully supervised programme of chemotherapy for pulmonary tuberculosis given once weekly in the continuation phase in the rural areas of Hong Kong
74. Tuberculosis in Kenya: follow-up of the second (1974) national sampling survey and a comparison with the follow-up data from the first (1964) national sampling survey
75. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs
76. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme
77. The outcome of chemopro-phylaxis on tuberculosis prevention in the Canadian Plains Indian
78. Patient compliance: are we wasting our time and don’t know it? [editorial]
79. When tuberculosis treatment fails: a social behavioral account of patient adherence
80. Directly observed treatment of tuberculosis, we can’t afford not to try it
81. Beyond four drugs, public health policy and the treatment of the individual patient with tuberculosis
82. High-compliance tuberculosis treatment programme in a rural community
83. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis
84. Mycobacterium tuberculosis
85. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis, a twice-weekly, directly observed, and cost-effective regimen
86. Tuberculosis: a six-month cure
87. Cost savings from alternative treatments for tuberculosis
88. Drug-resistant tuberculosis: laboratory issues, World Health Organization recommendations
89. Detection of rifampi-cin-resistance mutations in Mycobacterium tuberculosis
90. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis
91. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
92. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli
93. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet
94. Studies of bioavailability in man
95. Current practices in myco-bacteriology: results of a survey of state public health laboratories
96. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement
97. Drug resistance of Mycobacterium tuberculosis in Korea
98. Short-course chemotherapy for extrapulmonary tuberculosis; nine years’ experience
99. Six-months versus nine-months chemotherapy for tuberculosis of lymph nodes: preliminary results
100. Short course chemotherapy for tuberculous lymphadenitis in children
101. Six-month combination chemotherapy for cervical tuberculous lymphadenitis
102. The ambulant treatment of spinal tuberculosis
103. A 10-year assessment of controlled trials of inpatient and outpatient treatment and of plaster-of-paris jackets for tuberculosis of the spine in children on standard chemotherapy
104. Bactériologie de la tuberculose ostéo-arti-culaire sous chimothérapie
105. Controlled trial of short-course regimens of chemotherapy in the ambulatory treatment of spinal tuberculosis
106. A controlled trial of short-course regimens of chemotherapy in patients receiving ambulatory treatment or undergoing radical surgery for tuberculosis of the spine
107. Chemotherapy for tuberculosis in infants and children
108. Current chemotherapy for tuberculosis in children
109. A 10-year assessment of a controlled trial comparing debridement and anterior spinal fusion in the management of tuberculosis of the spine in patients on standard chemotherapy in Hong Kong
110. A controlled trial of anterior spinal fusion and debridement in the surgical management of tuberculosis of the spine in patients on standard chemotherapy: a study in two centres in South Africa
111. Tuberculosis of the spine: a review
112. Bone and joint tuberculosis
113. A controlled trial of debridement and ambulatory treatment in the management of tuberculosis of the spine in patients on standard chemotherapy
114. Pott’s paraplegia: an account of the treatment of 89 consecutive patients
115. Pott’s paraplegia, a clinical review of operative and conservative treatment in 63 adults and children
116. Tuberculous spondylitis, a report of six cases and a review of the literature
117. Treatment of tuberculous meningitis with 6-month course of chemotherapy
118. Tuberculous meningitis, short course of chemotherapy
119. Dexametha-sone in tuberculous meningitis
120. Mortality from tuberculous meningitis reduced by steroid therapy
121. Clinical analysis of 445 cases of adult tuberculous meningitis
122. Dexamethasone as an adjunct to treatment of tuberculous meningitis
123. Corticosteroids as an adjuvant to the chemotherapy of tuberculous meningitis
124. The place of corticosteroids in the management of tuberculous meningitis
125. The treatment of tuberculous meningitis
126. Tuberculosis and pregnancy: five to ten year review of 215 patients in their fertile age
127. Pregnancy-associated depression of cell-mediated immunity
128. Tuberculosis and pregnancy
129. Perinatally acquired neonatal tuberculosis: report of 2 cases
130. Treatment of tuberculosis during pregnancy
131. Failure of ‘optimal’ four-drug short-course tuberculosis chemotherapy in a compliant patient with human immunodeficiency virus
132. Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid
133. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results
134. Increased mortality and tuberculosis treatment failure among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with ‘standard’ chemotherapy in Kinshasa, Zaire
135. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET)
136. The acquired immune deficiency syndrome with special reference to tuberculosis
137. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection
138. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya
139. Tuberculosis and human immunodeficiency virus infection in Africa
140. The association of tuberculosis and HIV infection in Harare, Zimbabwe
141. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated B2-microglobulin in HIV-1-associated tuberculosis
142. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
143. Tuberculosis in the 1990’s
144. A prospective study of the risk of tuberculosis among intravenous drug users with HIV infection
145. Epidemiology of tuberculosis
146. Efficacy of various durations of isonazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial
147. Controlled chemoprophylaxis trials in tuberculosis: a general review
148. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies
149. Risk for developing tuberculosis among anergic patients infected with HIV
150. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tubverculosis
151. Preventive treatment for tuberculosis control in developing countries: the case for preventive chemotherapy
152. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention
153. Tuberculosis in Africa in the AIDS era - the role of chemoprophylaxis
154. Isoniazid-related hepatitis
155. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis
156. New experimental regimens for preventive therapy of tuberculosis
157. Management of persons exposed to multidrug-resistant tuberculosis
158. A double-blind controlled trial of chemoprophylaxis against tuberculosis in patients with silicosis in Hong Kong